Soligenix receives hong kong patent for therapeutic use of synthetic hypericin to treat cutaneous t-cell lymphoma

Princeton, n.j., feb. 1, 2021 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the hong...
SNGX Ratings Summary
SNGX Quant Ranking